دورية أكاديمية
Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel.
العنوان: | Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel. |
---|---|
المؤلفون: | Sharma D; Vanderbilt University Medical Center, Nashville, TN., Kozanoğlu I; Department of Physiology, Faculty of Medicine, Başkent University, Ankara, Turkey.; Adana Adult Bone Marrow Transplantation Center (CIC. 589), Apheresis Unit, Başkent University, Yuregir, Adana, Turkey., Ataga KI; Center for Sickle Cell Disease, University of Tennessee Health Science Center, Memphis, TN., Benachi A; Division of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, Antoine Béclère Hospital, Assistance Publique Hôpitaux de Paris, Paris Saclay University Hospitals, Clamart, France., Büyükkurt S; Department of Obstetrics and Gynecology, Faculty of Medicine, Çukurova University, Adana, Turkey., Lanzkron S; Division of Hematology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD., Ozdogu H; Department of Hematology, Faculty of Medicine, Başkent University, Ankara, Turkey.; Adana Adult Bone Marrow Transplantation Center (CIC. 589), Apheresis Unit, Başkent University, Yuregir, Adana, Turkey., Pancham S; Department of Haematology, Sandwell and West Birmingham Hospitals National Health Service Trust, West Bromwich, United Kingdom., Pecker LH; Division of Hematology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD.; Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, MD., Robinson SE; Department of Women's Health, Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom., Yilmaz Baran S; Department of Obstetrics and Gynecology, Başkent University, Dr. Turgut Noyan Application and Research Center, Adana, Turkey., Howard J; Department of Clinical Haematology, Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom. |
المصدر: | Blood advances [Blood Adv] 2024 Feb 27; Vol. 8 (4), pp. 1018-1029. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Washington, DC : American Society of Hematology, [2016]- |
مواضيع طبية MeSH: | Anemia, Sickle Cell*/complications , Anemia, Sickle Cell*/therapy , Acute Chest Syndrome*/therapy , Acute Chest Syndrome*/complications, Humans ; Female ; Pregnancy ; Blood Transfusion/methods ; Hydroxyurea/therapeutic use ; Aspirin |
مستخلص: | Abstract: Data to guide evidence-based management of pregnant people with sickle cell disease (SCD) are limited. This international Delphi panel aimed to identify consensus among multidisciplinary experts for SCD management during pregnancy. The 2-round Delphi process used questionnaires exploring 7 topics (antenatal care, hydroxyurea use, transfusion, prevention of complications, treatment of complications, delivery and follow-up, and bottlenecks and knowledge gaps) developed by a steering committee. Thirteen panelists (hematologists, physiologists, obstetricians, maternal fetal medicine, and transfusion medicine physicians) from the United States, the United Kingdom, Turkey, and France completed the first survey; 12 panelists completed the second round. Anonymized responses were collected and summarized by a contract research organization (Akkodis Belgium). Consensus and strong consensus were predefined as 75% to 90% (9-10 of 12) and >90% (≥11 of 12) of panelists, respectively, agreeing or disagreeing on a response to a predefined clinical scenario or statement. In several areas of SCD management, consensus was achieved: experts recommended performing at least monthly multidisciplinary antenatal follow-up, administering prophylactic aspirin for preeclampsia prevention between gestational weeks 12 and 36, initiating prophylactic transfusion therapy in certain cases, or choosing automated red blood cell exchange over other transfusion methods for patients with iron overload or severe acute chest syndrome. No consensus was reached on several topics including the prophylactic aspirin dose, indications for starting infection prophylaxis, routine use of prophylactic transfusions, or use of prophylactic transfusions for preventing fetal complications. These recommendations could inform clinical care for patients with SCD who are pregnant in the absence of large clinical trials involving this population; the identified knowledge gaps can orient future research. (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.) |
References: | Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):625-631. (PMID: 27913538) Am J Obstet Gynecol. 2021 Jan;224(1):95.e1-95.e12. (PMID: 32687818) Am J Hematol. 2016 Jan;91(1):5-14. (PMID: 26547630) Am J Hematol. 2019 Dec;94(12):E328-E331. (PMID: 31571271) Blood Adv. 2020 Jan 28;4(2):327-355. (PMID: 31985807) Haematologica. 2019 Sep;104(9):1710-1719. (PMID: 31413089) Br J Haematol. 2021 Sep;194(6):980-995. (PMID: 34409598) Trials. 2020 Apr 20;21(1):347. (PMID: 32312326) Rev Med Interne. 2015 May 11;36(5 Suppl 1):5S3-84. (PMID: 26007619) Am J Hematol. 1999 Feb;60(2):148-50. (PMID: 9929109) Front Pharmacol. 2022 Jan 10;12:770640. (PMID: 35082665) Palliat Med. 2017 Sep;31(8):684-706. (PMID: 28190381) Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):359-366. (PMID: 31808864) Trials. 2023 Mar 24;24(1):225. (PMID: 36964626) BMJ Open. 2021 Aug 13;11(8):e047949. (PMID: 34389570) Hematology Am Soc Hematol Educ Program. 2015;2015:436-43. (PMID: 26637755) Crit Rev Oncol Hematol. 2016 Feb;98:364-74. (PMID: 26672916) Semin Hematol. 2018 Apr;55(2):102-112. (PMID: 30616806) Prof Case Manag. 2018 Jul/Aug;23(4):213-219. (PMID: 29846351) Trials. 2018 Jan 29;19(1):78. (PMID: 29378652) N Engl J Med. 1988 Dec 1;319(22):1447-52. (PMID: 3054555) Biomedicines. 2023 Feb 17;11(2):. (PMID: 36831132) Am J Hematol. 2022 May;97(5):603-612. (PMID: 35142007) Hemasphere. 2020 Aug 12;4(4):e446. (PMID: 32885142) J Matern Fetal Neonatal Med. 2022 Dec;35(25):9383-9390. (PMID: 35109759) Blood. 2015 Nov 19;126(21):2424-35; quiz 2437. (PMID: 26302758) J Natl Med Assoc. 2009 Oct;101(10):1046-51. (PMID: 19860305) Transfusion. 2012 Dec;52(12):2671-6. (PMID: 22519830) J Adv Nurs. 2000 Oct;32(4):1008-15. (PMID: 11095242) J Clin Epidemiol. 2014 Apr;67(4):401-9. (PMID: 24581294) Pharmacy (Basel). 2022 Sep 26;10(5):. (PMID: 36287444) Mediterr J Hematol Infect Dis. 2019 Jul 01;11(1):e2019040. (PMID: 31308916) Birth Defects Res B Dev Reprod Toxicol. 2007 Aug;80(4):259-366. (PMID: 17712860) |
المشرفين على المادة: | X6Q56QN5QC (Hydroxyurea) R16CO5Y76E (Aspirin) |
تواريخ الأحداث: | Date Created: 20240111 Date Completed: 20240219 Latest Revision: 20240224 |
رمز التحديث: | 20240224 |
مُعرف محوري في PubMed: | PMC10879679 |
DOI: | 10.1182/bloodadvances.2023011301 |
PMID: | 38206762 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2473-9537 |
---|---|
DOI: | 10.1182/bloodadvances.2023011301 |